2024-07-23 ã«ããªã³ã¹ã«ç 究æ(KI)
ã«ããªã³ã¹ã«ç 究æã®ç 究è
ã«ãã£ãŠéçºãããã¹ããã¯ãã«ã 3(Stockholm3)è¡æ¶²æ€æ»ã¯ãç°ãªãæ°æã°ã«ãŒãã«ãããŠãåç«è
ºãããæ€åºããå¹æãåçã§ãããåŸæ¥ã®PSAæ€æ»ãããåªããçµæã瀺ããŸããStockholm3ã¯è¡æ¶²ãµã³ãã«ã®ã¿ã³ãã¯è³ªãšéºäŒããŒã«ãŒãçµã¿åãããã¢ã«ãŽãªãºã ãçšããŠãèšåºçã«éèŠãªçã®ç¢ºçãç®åºããŸãã
â90,000人以äžã®ç·æ§ã察象ãšããç 究ã§ã¯ããã®æ€æ»ãPSAæšæºæ€æ»ãããåªããçµæãåºããäžèŠãªMRIãçæ€ãæžãããäœPSAå€ã®ç·æ§ã§ãéèŠãªçãç¹å®ããããšã瀺ãããŸãããã¢ã¡ãªã«ãšã«ããã®å€æ§ãªæ°æã°ã«ãŒãã察象ãšããç 究ã§ãåæ§ã®çµæãåŸãããäžèŠãªçæ€ãçŽååã«æžããããšã確èªãããŸããããã®ç 究ã¯ã¹ããã¯ãã«ã 3ãçœäººä»¥å€ã®äººã
ã«ãæå¹ã§ããããšã瀺ããæ¹æ³ã®æ®åãæåŸ
ãããŸãã
<é¢é£æ å ±>
- https://news.ki.se/prostate-cancer-blood-test-equally-effective-across-ethnic-groups
- https://ascopubs.org/doi/10.1200/JCO.24.00152
åç«è ºããçºèŠã®ããã®å€æ°æã³ããŒãã«ãããã¹ããã¯ãã«ã 3(SEPTA): å€æœèšå ±åååãè©Šéš Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial
Hari T. Vigneswaran, MD , Martin Eklund, PhD , Andrea Discacciati, PhD, Tobias Nordström, MD, PhD, Rebecca A. Hubbard, PhD , Nathan Perlis, MD, Michael R. Abern, MD, âŠ
Journal of Clinical Oncology Published:July 22, 2024
DOI:https://doi.org/10.1200/JCO.24.00152
Abstract
Purpose
Asian, Black, and Hispanic men are underrepresented in prostate cancer (PCa) clinical trials. Few novel prostate cancer biomarkers have been validated in diverse cohorts. We aimed to determine if Stockholm3 can improve prostate cancer detection in a diverse cohort.
Methods
An observational prospective multicentered (17 sites) clinical trial (2019-2023), supplemented by prospectively recruited participants (2008-2020) in a urology clinic setting included men with suspicion of PCa and underwent prostate biopsy. Before biopsy, sample was collected for measurement of the Stockholm3 risk score. Parameters include prostate-specific antigen (PSA), free PSA, KLK2, GDF15, PSP94, germline risk (single-nucleotide polymorphisms), age, family history, and previous negative biopsy. The primary endpoint was detection of International Society of Urological Pathology (ISUP) Grade â¥2 cancer (clinically significant PCa, csPC). The two primary aims were to (1) demonstrate noninferior sensitivity (0.8 lower bound 95% CI noninferiority margin) in detecting csPC using Stockholm3 compared with PSA (relative sensitivity) and (2) demonstrate superior specificity by reducing biopsies with benign results or low-grade cancers (relative specificity).
Results
A total of 2,129 biopsied participants were included: Asian (16%, 350), Black or African American (Black; 24%, 505), Hispanic or Latino and White (Hispanic; 14%, 305), and non-Hispanic or non-Latino and White (White; 46%, 969). Overall, Stockholm3 showed noninferior sensitivity compared with PSA â¥4 ng/mL (relative sensitivity: 0.95 [95% CI, 0.92 to 0.99]) and nearly three times higher specificity (relative specificity: 2.91 [95% CI, 2.63 to 3.22]). Results were consistent across racial and ethnic subgroups: noninferior sensitivity (0.91-0.98) and superior specificity (2.51-4.70). Compared with PSA, Stockholm3 could reduce benign and ISUP 1 biopsies by 45% overall and between 42% and 52% across racial and ethnic subgroups.
Conclusion
In a substantially diverse population, Stockholm3 significantly reduces unnecessary prostate biopsies while maintaining a similar sensitivity to PSA in detecting csPC.
